Gurugram (Haryana) [India], a private hospital in Gurugram has acquired a patent for its innovative Medanta Anterior Oblique Lateral Oblique (MAOLO) template. This device can help address tumors up to 100c and even larger.
Dr. Naresh Trehan, President and CEO of Medanta, said: "At Medanta, our top priority is the well-being of our patients. The MAOLO workforce exemplifies our dedication to developing high-quality medical technologies that improve patient outcomes. This patent is not only a milestone for Medanta, but also an important step forward for cervical cancer care in India. “We will continue to innovate and provide solutions that meet the needs of our community.”
"It has been conceptualized by Dr. Susovan Banerjee, associate director, developed together with Dr. Tejinder Kataria, president of the Division of Radiation Oncology at the Cancer Institute and the Medanta Medical Physics Team. The MAOLO can help address tumors of up to 100 cc (cubic centimeters) and more, while commercially available intracavitary applicators are known to be effective against tumors of 36 cc or less in volume," said a statement issued by the hospital.
According to the statement issued by Medanta, this innovation marks a significant improvement in the treatment of cervical cancer, which is the second most common cancer among women in India. Despite being 98 percent preventable with vaccines and Pap tests in the pre-disease stage, and 95 percent treatable in the initial stages of the disease, cervical cancer in India claims 2/ 3 of all patients due to its late-stage presentation, when large and bulky tumors have spread to the lateral pelvic wall.
Brachytherapy, also called plesiotherapy, places the radiation source close to the tumor: on the surface of the skin, in the mucous membranes, inside the tissue or in the cavities. It uses a higher total dose of radiation to treat a smaller area than external beam radiation therapy, which directs high-energy X-rays (radiation) at tumors from outside the body. Since the 1930s, brachytherapy has been used to treat mouth or tongue cancer, soft tissue sarcomas (for limb sparing), and cervical cancer with excellent results.
Dr. Tejinder Kataria, Chairman, Radiation Oncology, Medanta Cancer Institute, said, "In India, commercially available interstitial and intracavitary combination applicators are bulky and restricted in scope. They require time, training and skill to assemble, such as as they come.
Dr. Susovan Banerjee, Associate Director of Radiation Oncology at Medanta, explains the inspiration for the device. "The available applicators, in addition to being bulky and cumbersome, have inadequate geometric coverage for large volumes of disease, leading to recurrences. Therefore, we saw the need to design a new device that could provide a local solution to our clinical conundrum. ".
"The MAOLO is a disc-shaped device that allows the maximum possible number of catheters to be placed in three directions. This design makes it useful in addressing some of the largest tumors that present clinically. The improved technology of this single-template piece eliminates the need for assembly makes it easier to use by technical staff and reduces the margin of error. Being cylindrical, MAOLO can be safely placed in the vagina, making it more comfortable and eliminating adverse effects such as significant bleeding. , pain, discomfort or geometric asymmetry (geographical error), issues that may lead to abandoning the procedure," explained Dr. Banerjee.
Dr. Naresh Trehan, President and CEO of Medanta, said: "At Medanta, our top priority is the well-being of our patients. The MAOLO workforce exemplifies our dedication to developing high-quality medical technologies that improve patient outcomes. This patent is not only a milestone for Medanta, but also an important step forward for cervical cancer care in India. “We will continue to innovate and provide solutions that meet the needs of our community.”
"It has been conceptualized by Dr. Susovan Banerjee, associate director, developed together with Dr. Tejinder Kataria, president of the Division of Radiation Oncology at the Cancer Institute and the Medanta Medical Physics Team. The MAOLO can help address tumors of up to 100 cc (cubic centimeters) and more, while commercially available intracavitary applicators are known to be effective against tumors of 36 cc or less in volume," said a statement issued by the hospital.
According to the statement issued by Medanta, this innovation marks a significant improvement in the treatment of cervical cancer, which is the second most common cancer among women in India. Despite being 98 percent preventable with vaccines and Pap tests in the pre-disease stage, and 95 percent treatable in the initial stages of the disease, cervical cancer in India claims 2/ 3 of all patients due to its late-stage presentation, when large and bulky tumors have spread to the lateral pelvic wall.
Brachytherapy, also called plesiotherapy, places the radiation source close to the tumor: on the surface of the skin, in the mucous membranes, inside the tissue or in the cavities. It uses a higher total dose of radiation to treat a smaller area than external beam radiation therapy, which directs high-energy X-rays (radiation) at tumors from outside the body. Since the 1930s, brachytherapy has been used to treat mouth or tongue cancer, soft tissue sarcomas (for limb sparing), and cervical cancer with excellent results.
Dr. Tejinder Kataria, Chairman, Radiation Oncology, Medanta Cancer Institute, said, "In India, commercially available interstitial and intracavitary combination applicators are bulky and restricted in scope. They require time, training and skill to assemble, such as as they come.
Dr. Susovan Banerjee, Associate Director of Radiation Oncology at Medanta, explains the inspiration for the device. "The available applicators, in addition to being bulky and cumbersome, have inadequate geometric coverage for large volumes of disease, leading to recurrences. Therefore, we saw the need to design a new device that could provide a local solution to our clinical conundrum. ".
"The MAOLO is a disc-shaped device that allows the maximum possible number of catheters to be placed in three directions. This design makes it useful in addressing some of the largest tumors that present clinically. The improved technology of this single-template piece eliminates the need for assembly makes it easier to use by technical staff and reduces the margin of error. Being cylindrical, MAOLO can be safely placed in the vagina, making it more comfortable and eliminating adverse effects such as significant bleeding. , pain, discomfort or geometric asymmetry (geographical error), issues that may lead to abandoning the procedure," explained Dr. Banerjee.
